Unresectable Hepatocellular Carcinoma Clinical Trial
Official title:
A Prospective, Single-arm, Phase II Clinical Study of the Efficacy and Safety of Donafenib Plus Sintilimab Combined With Transarterial Chemoembolization (TACE) in Patients With BCLC Stage B/C Hepatocellular Carcinoma
To evaluate the efficacy and safety of Donafenib plus Sintilimab in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma(HCC).
Transarterial chemoembolisation (TACE) was effective and safe for hepatocellular carcinoma. Donafenib was better than sorafenib in overall survival in untreated advanced hepatocellular carcinoma, and programmed cell death protein-1 (PD-1) antibody was effective and tolerable in patients with advanced hepatocellular carcinoma. No study has evaluated TACE plus donafenib and sintilimab. Thus, the investigators carried out this prospective, single-arm study to find out it. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT00988741 -
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy
|
Phase 2 | |
| Recruiting |
NCT03942328 -
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01900002 -
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 2 | |
| Completed |
NCT06315101 -
Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
|
||
| Not yet recruiting |
NCT04947956 -
Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma
|
||
| Completed |
NCT01004978 -
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
Phase 3 | |
| Active, not recruiting |
NCT01217034 -
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
|
Phase 2 | |
| Terminated |
NCT03695250 -
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT02006030 -
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT03896646 -
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
|
N/A | |
| Recruiting |
NCT05135364 -
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure
|
Phase 2 | |
| Recruiting |
NCT06117891 -
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
|
||
| Recruiting |
NCT05957640 -
Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 1 | |
| Recruiting |
NCT04736121 -
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
|
N/A | |
| Recruiting |
NCT05168163 -
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
|
Phase 2 | |
| Withdrawn |
NCT03345225 -
A Clinical Study of Precision TACE (P-TACE) With Surefire
|
N/A | |
| Recruiting |
NCT05667064 -
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
|
||
| Recruiting |
NCT05269381 -
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02989870 -
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
|
Phase 1 |